Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Circulatory system drugs >  Antiarrhythmics Drugs >  BRETYLIUM TOSYLATE

BRETYLIUM TOSYLATE

Basic information Safety Supplier Related

BRETYLIUM TOSYLATE Basic information

Product Name:
BRETYLIUM TOSYLATE
Synonyms:
  • (o-bromobenzyl)ethyldimethyl-ammoniup-toluenesulfonate
  • 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium4-methylbenzenesulfonate
  • 2-bromo-n-ethyl-n,n-dimethyl-benzenemethanaminiusaltwith4-methylbenzen
  • darentin
  • dimethylethyl-o-bromobenzylammonium-p-toluenesulphonate
  • esulfonicacid
  • n-ethyl-n-o-bromobenzyl-n,n-dimethylammoniumtosylate
  • ornid
CAS:
61-75-6
MF:
C18H24BrNO3S
MW:
414.36
EINECS:
200-516-8
Product Categories:
  • Amines
  • Aromatics
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Mol File:
61-75-6.mol
More
Less

BRETYLIUM TOSYLATE Chemical Properties

Melting point:
97-99°
storage temp. 
Inert atmosphere,Room Temperature
solubility 
H2O: soluble50mg/mL
color 
white
InChIKey
KVWNWTZZBKCOPM-UHFFFAOYSA-M
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
20/21/22
Safety Statements 
36
RTECS 
BO9450000
HS Code 
2923900100
Toxicity
LD50 in mice (mg/kg): 400 orally; 250 i.m. (Goldenthal)
More
Less

BRETYLIUM TOSYLATE Usage And Synthesis

Chemical Properties

White Solid

Originator

Bretylate,Wellcome,UK,1973

Uses

Bretylium tosylate has a biphasic response, initially inducing norepinephrine release followed by sympathetic ganglionic blockade. Bretylium tosylate is a class III antiarrhythmic agent and a competitive inhibitor of acetylcholinesterase.

Definition

ChEBI: The tosylate salt of bretylium. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibril ation.

Manufacturing Process

N-o-Bromobenzyl-N,N-dimethylamine (100g) and ethyl p-toluenesulfonate (94 g) were mixed and warmed to 50°-60°C; after standing for either (a) a minimum of 96 hours at 15°-20°C or (b) a minimum of 18 hours at 50°-60°C and cooling to room temperature, a hard, crystalline mass was formed. Recrystallization of this product from acetone (2.0 ml/g of crude solid), followed by filtration and drying to 60°C gave N-o-bromobenzyl-N-ethyl-N,Ndimethylammonium p-toluenesulfonate as a white, crystalline solid, MP 97°- 99°C. For this procedure it was necessary that the reactants were substantially colorless and of a high purity.

brand name

Bretylol (Mayne).

Therapeutic Function

Adrenergic blocker; Antiarrhythmic

General Description

Bretylium tosylate, (o-bromobenzyl)ethyl dimethylammonium p-toluenesulfonate(Bretylol), is an extremely bitter, white, crystalline powder.The chemical is freely soluble in water and alcohol.Bretylium tosylate is an adrenergic neuronal-blockingagent that accumulates selectively in the neurons anddisplaces norepinephrine. Because of this property,bretylium was used initially, under the trade name ofDarenthin, as an antihypertensive agent. It caused posturaldecrease in arterial pressure. This use was discontinuedbecause of the rapid development of tolerance, erratic oralabsorption of the quaternary ammonium compound, andpersistent pain in the parotid gland on prolonged therapy.

Clinical Use

Currently, bretylium is reserved for use in ventriculararrhythmias that are resistant to other therapy. Bretyliumdoes not suppress phase 4 depolarization, a common actionof other antiarrhythmic agents. It prolongs the effectiverefractory period relative to the action potential durationbut does not affect conduction time and is categorized asa class III antiarrhythmic agent. Because bretylium doesnot have properties similar to those of the other antiarrhythmicagents, it has been suggested that its action is aresult of its adrenergic neuronal-blocking properties; theantiarrhythmic properties of the drug, however, are notaffected by administration of reserpine. Bretylium is also alocal anesthetic, but it has not been possible to demonstratesuch an effect on atria of experimental animals, except atvery high concentrations. Therefore, the precise mechanismof the antiarrhythmic action of bretylium remains tobe resolved.

Side effects

The major adverse effect associated with bretylium tosylate is hypotension, including orthostatic hypotension, which may be very severe.

BRETYLIUM TOSYLATE Preparation Products And Raw materials

Raw materials

BRETYLIUM TOSYLATESupplier

J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Email
sj_scrc@sinopharm.com
Maya High Purity Chemicals
Tel
+86 (573) 82222445 (0)18006601000 QQ:452520369
Email
sales@maya-r.com
Wuhan ariel chemical Co., LTD.
Tel
027-87840182-
Email
sales@3stc.com